Cerecor (CERC)

Cerecor Inc., a biopharmaceutical company, focuses on the development and commercialization of treatments for rare and orphan diseases. The company develops monosaccharide therapies for the treatment of congenital disorders of glycosylation, such as CERC-801, CERC-802, and CERC-803. It is also involved in the development of CERC-007, an anti-IL-18 monoclonal antibody for the treatment of adult onset Still's disease and multiple myeloma, as well as for the treatment of systemic juvenile idiopathic arthritis. Additionally, Cerecor is developing CERC-006, an oral mTORC1/2 inhibitor to treat complex lymphatic malformations, and CERC-002, an anti-LIGHT monoclonal antibody that is in phase 2 clinical trials for the treatment of COVID-19 acute respiratory distress syndrome, as well as for the treatment of pediatric-onset Crohn's disease. In addition, the company offers Millipred, an oral prednisolone for the treatment of inflammatory conditions, such as arthritis, blood disorders, immune system disorders, skin and eye conditions, respiratory disorders, cancer, and severe allergies. Cerecor Inc. has a collaboration agreement with The Frontiers in Congenital Disorders of Glycosylation Consortium on a pivotal trial of CERC-801 for the treatment of Phosphoglucomutase-1 deficiency related congenital disorders of glycosylation. The company was formerly known as Ceregen Corporation and changed its name to Cerecor Inc. in March 2011. Cerecor Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.